LeslieASpikesMD

Pulmonology • Kansas City, KS

Critical Care Medicine, Pleural Disease

Assistant Professor, Internal Medicine, University Kansas School of Medicine

Join to view full profile

Dr. Spikes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Spikes' full profile

Already have an account?

Office
University of Kansas Medical Center 3901
MS 3007
Kansas City, KS 66160
Phone+1 913-588-6046

Fax+1 913-888-8814

Education & Training

University of Kansas School of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 2007 - 2010
University of Kansas School of MedicineResidency, Internal Medicine, 2004 - 2007
University of Kansas School of MedicineClass of 2004

Certifications & Licensure

KS State Medical License 2007 - 2025
MO State Medical License 2021 - 2025
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH Start of enrollment: 2018 Jul 15
Terminated
Phase 2
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 Start of enrollment: 2019 Apr 10
Terminated
Phase 2
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Start of enrollment: 2020 Jul 15
Terminated
Phase 2
COVID-19 Biorepository Start of enrollment: 2020 Apr 15
Recruiting
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2) Start of enrollment: 2021 Mar 15
Completed
Phase 2
Post COVID-19 Biorepository Start of enrollment: 2021 Feb 08
Recruiting
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Burden of illness in patients with pulmonary hypertension due to interstitial lung disease: a real-world analysis.
Gustavo Heresi, Bonnie Dean, Benjamin Wu, Henry Lee, Margaret R Sketch
BMC Pulmonary Medicine. 2024-07-11
56 citations
Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19.
Vaughn Craddock, Aatish Mahajan, Leslie Spikes, Balaji Krishnamachary, Anil K Ram
Journal of Medical Virology. 2023-02-01
3 citations
Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design.
Raymond L Benza, Veronica Franco, Mandar A Aras, Leslie Spikes, Daniel Grinnan
Respiratory Research. 2022-12-17

Press Mentions

United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-Term Data in the Journal Pulmonary CirculationApril 6th, 2022
KC Doctors Worried About Number of COVID Deaths, Long-Hauler SymptomsJanuary 13th, 2022
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021September 7th, 2021
Join now to see all